Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Bristol-Myers Squibb Continues to Reward Investors, Announces Increased Dividend

December 20, 2024
Bristol-Myers Squibb Company (NYSE:BMY) has just announced that it will be paying a larger dividend than last year, showing its commitment to rewarding its shareholders. The biopharmaceutical giant will be paying out a dividend of $0.62 per share, an increase from the previous year. This news comes as the company continues to experience strong financial performance and solid growth in its key therapeutic areas. Investors looking to benefit from the positive outlook of Bristol-Myers Squibb may consider seeking professional advice from experts at Stocks Prognosis to forecast the potential movement of the company's stock.

Find out how the BRISTOL-MYERS SQUIBB COMPANY rate is expected to change

Get Forecast for BMY

Investor opinions & comments:

I'm bullish on Bristol-Myers Squibb's future prospects and this increased dividend justifies my optimism
— from MarketMason at 12-22-2024 19:21
I'm skeptical about the sustainability of this dividend increase. I want to see more consistent growth before considering an investment
— from DividendDylan at 12-22-2024 15:15
I'm glad to see Bristol-Myers Squibb rewarding their investors. It shows their commitment to shareholder value
— from AvaTurner at 12-22-2024 10:20
This dividend increase reinforces my confidence in Bristol-Myers Squibb as a stable and profitable investment
— from JeremiahSnyder at 12-22-2024 01:27
This is great news for shareholders! I'm excited to see how this increased dividend will impact the stock price
— from OliviaJackson at 12-21-2024 23:20
I've been considering investing in Bristol-Myers Squibb and this news has convinced me that now is a great time to buy
— from SavannahGordon at 12-21-2024 15:54
Bristol-Myers Squibb's increased dividend is a clear sign that the company is confident in its financial strength
— from ZoeRoss at 12-21-2024 07:33
I'm impressed with Bristol-Myers Squibb's commitment to rewarding shareholders. This is a company I want to invest in
— from JoshuaAdams at 12-21-2024 06:23
I'm a shareholder in Bristol-Myers Squibb and I'm thrilled to see the company rewarding its investors with a higher dividend
— from SophiaHarris at 12-20-2024 15:40
This news is a testament to Bristol-Myers Squibb's strong performance and growth. I'm confident in their future success
— from LucasPrice at 12-20-2024 14:17
I've been a long-term investor in Bristol-Myers Squibb and this dividend increase is a welcome surprise
— from JessicaHall at 12-20-2024 10:55
I'll wait to see how this dividend increase affects the company's overall financial health before making any investment decisions
— from BudgetBrittany at 12-20-2024 08:42
Bristol-Myers Squibb's strong financial performance and increased dividend make it an attractive investment option
— from MoneyMia at 12-20-2024 06:51
I'm not so sure about this news. The increase in dividend could be a sign that the company is struggling financially
— from CalebBishop at 12-20-2024 04:16
I have faith in Bristol-Myers Squibb's continued success and this increased dividend only solidifies my belief in the company
— from InvestorIan at 12-20-2024 04:13
If you want to leave a comment, then you need Login or Register





Other news for BMY

BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....

BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....

BMYMay 8, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target as QuantWave Forecast Achieves 7.55% Profit  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY has seen its stock reach the predicted price target set by QuantWave's automated forecasting platform....

BMYApril 10, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Forecast Target with 8.57% Profit: A Success Story for QuantWave  ~2 min.

BRISTOL-MYERS SQUIBB COMPANY (BMY) recently reached the price target forecasted by QuantWave, resulting in a profitable outcome for investors....



Related news

ABBVJanuary 29, 2025AbbVie Inc. Completes Acquisition of Nimble Therapeutics  ~2 min.

AbbVie Inc., a global biopharmaceutical company, has successfully completed its acquisition of Nimble Therapeutics, a biotherapeutics discovery company....

AZNOctober 31, 2024AstraZeneca PLC Collaborates with Monopar Therapeutics on Rare Disease Treatment  ~1 min.

Monopar Therapeutics, a biopharmaceutical company specializing in rare disease treatments, has announced a groundbreaking partnership with AstraZeneca PLC....

ABBVDecember 18, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics in a Game-Changing Move  ~1 min.

AbbVie Inc., a leading biopharmaceutical company, has announced its acquisition of Nimble Therapeutics, a pioneer in the field of immunology....

The Best Stocks for Magnificent Earnings Growth Next Year  ~3 min.

If you're on the lookout for stocks that are poised for impressive earnings growth in the coming year, look no further....

BIIBJanuary 28, 2025Sage Therapeutics Rejects Biogen Takeover Bid Explores Strategic Alternatives BIIB Stock News  ~2 min.

Sage Therapeutics, a leading biopharmaceutical company, recently made headlines as it rejected a takeover bid from Biogen Inc. This move came as a surprise to many in the industry, as Biogen Inc....